Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies
Progress in Cardiovascular Diseases · 2026
DOI: 10.1016/j.pcad.2026.06.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2026. Verfasst von Yashendra Sethi und 3 weiteren Autor:innen. Beteiligte Einrichtung: PearResearch, Dehradun 248001, India; Department of Medicine, Subharti Medical College, Swami Vivekanand Subharti University, Meerut 250005, India; N…. Hauptthemen laut MEDLINE: Precision Medicine, Cardiovascular Diseases, Dyslipidemias, Hypolipidemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
The landscape of lipid management has transitioned from a statin-monotherapy and statin-intensification paradigm to a sophisticated, multi-axis intervention model targeting low-density lipoprotein cholesterol, triglyceride-rich lipoproteins, lipoprotein(a), and vascular inflammation. The emergence of PCSK9-targeted small interfering RNA therapies, CETP inhibitors, and Lp(a)-directed antisense and RNA based agents has enabled complementary modulation of diverse lipid pathways through distinct molecular targets. However, this increasingly multidrug approach may also increase treatment complexity, healthcare burden, and adherence challenges, particularly among high-risk patients already receiving multidrug cardiometabolic therapy. Although intensive and sustained LDL-C lowering remains foundational to preventive cardiology, the real-world effectiveness of increasingly complex treatment strategies may ultimately depend on long-term adherence, affordability, patient capacity, and implementation feasibility. We propose a Clinical Prioritization and Personalization Framework centered on individualized risk-based intensification, comprehensive residual risk management, and optimization of treatment delivery to achieve sustainable, patient-centered cardiovascular protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PearResearch, Dehradun 248001, India; Department of Medicine, Subharti Medical College, Swami Vivekanand Subharti University, Meerut 250005, India; National Institute of Cardiometabolic Excellence (NICE), Vigyaved Healt…
- Department of Cardiology, Himachal Heart Institute, Mandi, Himachal Pradesh 175021, India.
- Department of Medicine, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157, United States of America.
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; Faculty of Medicine, The John Paul II Catholic University of Lublin, Poland; Liverpool Centre for Cardiovascular Scienc…
Zitieren
APA
Sethi, Y., Mahajan, K., Shapiro, M. D., & Banach, M. (2026). Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2026.06.004
Vancouver
Sethi Y, Mahajan K, Shapiro MD, Banach M. Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies. Progress in Cardiovascular Diseases. 2026. doi:10.1016/j.pcad.2026.06.004
BibTeX
@article{Sethi2026,
author = {Sethi, Yashendra and Mahajan, Kunal and Shapiro, Michael D and Banach, Maciej},
title = {Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies},
journal = {Progress in Cardiovascular Diseases},
year = {2026},
doi = {10.1016/j.pcad.2026.06.004}
}
EUVIMED